VentriPoint Diagnostics Ltd VPTDF

Primary Symbol: V.VPT

Healthcare Medical Devices

Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).

TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > The return flights from a trip to Europe

<< Previous

Bullboard Posts

Next >>

Comment by jopatcloon May 17, 2024 11:01am

45 Views

Post# 36045464

RE:The return flights from a trip to Europe

Impressive 10% of 1600 delegates
Nearly 10% of the attendees registered to participate in our workshops which indicates a growing awareness of the benefits that VMS+ offers.
The team is now following up with attendees
and will assist those who are motivated to adopt VMS+ into clinical practice.
Hugh post The calm before the storm.''We look forward to meeting the 1600 delegates at this years meeting and hosting workshops providing live demonstrations of VMS+''.

Good comment hassy latest post from Hugh https://www.linkedin.com/feed/update/urn:li:activity:7197018603269836800/ "...While in Italy it was interesting to learn of the limitations to workflow inherent to cMRI, and that there is an interest in the ability of VMS+ to streamline workflow, shorten turnaround times and improve the adult patient experience. Our discussions were focused towards right side heart function, and the potential to use VMS+ to assess patients suspected of having diseased or damaged tricuspid valves.
" Follow the bread crumb- if VPT can assist in speeding up the assessment of patient with damage heart valves, who would benefit most (other than the patient?).....The heart valves manufacturers, including large players such as Abbott!@TDGAFAU @jgb1993 You ask about the revenue model, let's think about how much value we can bring to these valve manufacturers :) This would be on TOP of the pediatric scenario I posted earlier.

<< Previous

Bullboard Posts

Next >>

A junior copper-gold stock trading at a bargain of monumental proportions